EPISODE · Aug 5, 2025 · 3 MIN
Lilly的控血糖药物Mounjaro心血管试验达标，但未显著优于Trulicity -- 250731
from 生物科技 · host Rei
Eli Lilly 的明星药物 Mounjaro（替尔泊肽）在一项大型心血管终点三期临床试验中达到主要终点，但未能在降低心血管事件方面显著优于其旧药 Trulicity（度拉糖肽）。尽管如此，Mounjaro 在控糖和减重方面的表现仍具吸引力，Lilly 计划今年提交申请，扩展其心血管适应症。Mounjaro能否在GLP-1类药物激烈竞争中脱颖而出？一起关注本期解读。
Embed this episode
Ready to play
Lilly的控血糖药物Mounjaro心血管试验达标，但未显著优于Trulicity -- 250731
0:00
3:14
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 生物科技?
This episode is 3 minutes long.
When was this 生物科技 episode published?
This episode was published on August 5, 2025.
Can I download this 生物科技 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!